Adalimumab: A new tumor necrosis factor antagonist and the treatment of Crohn′s disease

Saudi Journal of Gastroenterology

Volumn 13, Issue 2, 2007, Pages 98-100

  Helmy, Ahmed ^a   Al Kahtani, Khalid ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

Anti TNF antibody; Fistulizing Crohn s disease; Inflammatory bowel disease

Indexed keywords

EID: 34248330853     PISSN: 13193767     EISSN: None     Source Type: Journal    
DOI: 10.4103/1319-3767.32187     Document Type: Article

References (27)

1. Targan SR, Hanauer SB, van Deventer SJ, Mayer I, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-35.
2. Mannon PJ, Fuss IJ, Mayer L, Hson CO, Sandborn WJ, Present D, et al. Anti-interleukin-12 antibody for active Qrohn's disease. N Engl J Med 2004;351:2069-79.
3. Sawada K, Kusugami K, Suzuki Y, Bamba T, Munakata A, Hibi T, et al. Leukocytapheresis in ulcerative colitis: Results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment. Am J Gastroenterol 2005;100:1362-9.
4. Minami M, Ohta M, Ohkura T, Ando T, Ohmiya N, Niwa Y, et al. Ctyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330:1841-5.
5. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's disease: The ACCENTI randomized trial, Lancet 2002;359:1541-9.
6. Present HD, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405.
7. Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999;117:761-9.
8. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350:876-85.
9. Baert F, Noman M, Vermeire S, Van Assche G, D'Haens G, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-8.
10. Cheifetz A Smedley M, Martin S, Reiter M, Leone G, Mayer L, et al. The incidence and management of infusion reactions to infliximab: A large center experience. Am J Gastroenterol 2003;98:1315-24.
11. Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: A randomized controlled trial. Gastroenterology 2003;124:917-24.
12. Hanauer SR Wagner CL, Bala M, Mayer L, Travers S, Diamond RH, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004;2:542-53.
13. Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, et al. Adalimumab, a fully human and tumor necrosis factor-alpha monoclonal antibody and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003;30:2563-71.
14. Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH. eAdalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:3279-89.
15. Haibel H, Rudwaleit M, Brandt HC, Grozdanovic Z, Listing J, Kupper H, et al. Adalimumab reduces spinal symptoms in active ankylosing spondylitis. Arthritis Rheum 2006;54:678-81.
16. Gordon KB, Bonish BK, Patel T, Leonardi CL, Nickoloff BJ, The tumour necrosis factor-alpha inhibitor adalimumab rapidly reverses the decrease in epidermal Langerhans cell density in psoriatic plaques. Br J Dermatol 2005;153:945-53.
17. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: The CLASSIC-I trial. Gastroenterology 2006;130:323-33.
18. Sandborn WJ, Hanauer S, Enns R, Lukas M, Wolf D, Isaacs K, et al. Maintenance of remission over 1 year In patients with active Crohn's disease treated with adalimumab: Results of CLASSICII, a blinded, placebo-controlled study (oral presentartion OPG-353). Gut 2005;54:A81-2.
19. Colombel J, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Gastroenterology 2007;132:52-65.
20. Barthel HR, Gille T, Halbsguth A, Kramer M. Successful treatment with adalimumab in infliximab-resistant Crohn's disease. J Gastroenterol Hepatol 2005;20:1464-5.
21. Papadakis KA, Shaye OA, Vasiliauskas FA, Ippoliti A, Dubinsky MC, Birt J, et al. Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Am J Gastroenterol 2005;100:75-9.
22. Stallmach A, Giese T, Schmidt C, Meuer SC, Zeuzem SS. Severe anaphylactic reaction to infliximab: Successful treatment with adalimumab-report of a case. Eur J Gastroenterol Hepatol 2004;16:627-30.
23. Stallmach A, Giese T, Schmidt C, Meuer SC, Zeuzem SS. Severe anaphylactic reaction to infliximab: Successful treatment with adalimumab - report of a case. Eur J Gastroenterol Hepatol 2004;16:1984-9.
24. Hinojosa J, Gomollo NF, Garcia S, Bastida GJ, Cabriada, Saro CD, et al. Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: A prospective, open-label, multicentre trial. Aliment Pharmacol Ther 2007;25:409-18.
25. Burmester G, Pangan A, Kent JD, Lovell DJ, Gordon KB, Dijkmans BA, et al. Adalimumab is safe in global clinical trials in multiple indications and reduced mortality in rheumatoid arthritis. Ann Rheum Dis 2006;65:181-2.
26. Schiff MH, Burmester GR, Kent JM, Pangan AL, Kupper H, Fitzpatrick SB, et al. Safety analysis of adalimumab (HUMIRA) in global clinical trials and US post-marketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:889-94.
27. Sandborn WJ, Hanauer S, Lukas M, Wolf D, Isaacs K, MacIntosh D, et al. Clinical remission and response in patients with Crohn's Disease treated with open label for 1 year with fully human anti-TNF-α monoclonal antibody adalimumab (oral presentation OP-G-78). Gut 2005;54:A18.